SLZ0 Stock Chart & Stats
€4.67
€0.00(0.00%)
At close: 4:00 PM EDT
€4.67
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.67 - €4.79
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.36M
Enterprise Value-€2.79
Total Cash (Recent Filing)€8.30M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.73
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.46
Shares Outstanding4,475,884
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-272.82
Revenue Forecast (FY)€8.66M
Bulls Say, Bears Say
Bulls Say
Minimal DebtMinimal leverage reduces interest expense and refinancing risk, giving Enveric greater financial flexibility as it advances its drug candidates. This is a relative strength for a pre-revenue biotech that must preserve capital for research and development.
Improved Equity BaseThe stronger equity position provides a better capitalization base than in 2025 and may support continued operations and development activity. While equity has been volatile historically, the recent improvement enhances near-term balance-sheet resilience.
Reduced LossesAlthough Enveric remains unprofitable, the reduction in losses from earlier periods indicates some control over spending. Sustained expense discipline could extend the company’s development runway and help focus limited resources on its highest-value programs.
Bears Say
No Commercial RevenueThe absence of revenue means Enveric has no commercial cash inflow to fund operations or validate product-market demand. The company remains dependent on successful clinical development, regulatory progress, and eventual commercialization to establish a durable business.
Persistent Cash BurnSustained operating and free cash outflows require continued access to external capital until revenue or a major partnership milestone emerges. This limits financial independence and creates execution risk if funding conditions or investor support weaken.
Ongoing Dilution RiskRepeated equity issuance provides financing flexibility but can dilute existing shareholders and signals that internal cash generation is insufficient. Continued reliance on the ATM program may constrain per-share value unless funded programs produce meaningful development or commercial milestones.
Enveric Biosciences News
SLZ0 FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was €4.67 and its highest was €4.79 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is €5.36M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Nov 12, 2026 which is in 66 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on Aug 14, 2026. The company reported -€0.654 earnings per share for the quarter.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 4,475,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -€0.654 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in DE:SLZ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.